Roche R&D Spending Surge Reflects In-House Innovation, M&A Prices
‘Costs Being Squeezed Everywhere’ To Fund R&D
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.
You may also be interested in...
With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.
Management updated investors on M&A strategy, US drug pricing reform and R&D investment.
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.